{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:48:25Z","timestamp":1772192905129,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1124\/jpet.103.053942","type":"journal-article","created":{"date-parts":[[2003,9,19]],"date-time":"2003-09-19T00:50:21Z","timestamp":1063932621000},"page":"373-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration"],"prefix":"10.1016","volume":"307","author":[{"given":"H.","family":"Kuss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hoefgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Johanssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kronbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rundfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.053942_bib1","doi-asserted-by":"crossref","unstructured":"Andersson P (1980) Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs. Allergy 35: 65\u201371.","DOI":"10.1111\/j.1398-9995.1980.tb01718.x"},{"key":"10.1124\/jpet.103.053942_bib2","doi-asserted-by":"crossref","unstructured":"Ashton MJ, Cook DC, Fenton G, Karlsson JA, Palfreyman MN, Raeburn D, Ratcliffe AJ, Souness JE, Thurairaitnam S, and Vicker N (1994) Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues. J Med Chem 37: 1696\u20131703.","DOI":"10.1021\/jm00037a021"},{"key":"10.1124\/jpet.103.053942_bib3","doi-asserted-by":"crossref","unstructured":"Barnes PJ (1999) Therapeutic strategies for allergic diseases. Nature (Lond) 402: B31\u2013B38.","DOI":"10.1038\/35037026"},{"key":"10.1124\/jpet.103.053942_bib4","doi-asserted-by":"crossref","unstructured":"Barnes PJ (2000) Chronic obstructive pulmonary disease. N Engl J Med 343: 269\u2013280.","DOI":"10.1056\/NEJM200007273430407"},{"key":"10.1124\/jpet.103.053942_bib5","doi-asserted-by":"crossref","unstructured":"Barnette MS (1999) Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD), in Progress in Drug Research (Jucker E ed) vol 53, Birkh\u00e4user, Basel, Switzerland.","DOI":"10.1007\/978-3-0348-8735-9_5"},{"key":"10.1124\/jpet.103.053942_bib6","doi-asserted-by":"crossref","unstructured":"Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284: 420\u2013426.","DOI":"10.1016\/S0022-3565(24)37221-0"},{"key":"10.1124\/jpet.103.053942_bib7","doi-asserted-by":"crossref","unstructured":"Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297: 280\u2013290.","DOI":"10.1016\/S0022-3565(24)29538-0"},{"key":"10.1124\/jpet.103.053942_bib8","doi-asserted-by":"crossref","unstructured":"Burnouf C and Pruniaux M-P (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8: 1255\u20131296.","DOI":"10.2174\/1381612023394665"},{"key":"10.1124\/jpet.103.053942_bib9","doi-asserted-by":"crossref","unstructured":"Compton CH, Gubb J, Nieman R et al. (2001) Cilomilast, a selective phosphodiesterase 4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358: 265\u2013270.","DOI":"10.1016\/S0140-6736(01)05481-2"},{"key":"10.1124\/jpet.103.053942_bib10","unstructured":"Dale TJ, Ball DI, Nials AT, and Coleman RA (1995) The anti-inflammatory and emetogenic effects of phosphodiesterase (PDE) IV inhibitors in conscious ferrets. Br J Pharmacol 116: 91P"},{"key":"10.1124\/jpet.103.053942_bib11","doi-asserted-by":"crossref","unstructured":"Djukanovic R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, and Holgate ST (1990) Mucosal inflammation in asthma. Am Rev Respir Dis 142: 434\u2013457.","DOI":"10.1164\/ajrccm\/142.2.434"},{"key":"10.1124\/jpet.103.053942_bib12","doi-asserted-by":"crossref","unstructured":"Eum S-Y, Haile S, Lefort J, Huerre M, and Vargaftig BB (1995) Eosinophil recruitment into the respiratory epithelium following antigenic challenge in hyper-IgE mice is accompanied by interleukin 5-dependent bronchial hyperresponsiveness. Proc Natl Acad Sci USA 92: 12290\u201312294.","DOI":"10.1073\/pnas.92.26.12290"},{"key":"10.1124\/jpet.103.053942_bib13","unstructured":"Gasparic A, Schupke H, Olbrich M, Krone D, Peter G, Hempel R, and Kronbach T (2002) O-Glucoronidation as major metabolic pathway of the phosphodiesterase 4 inhibitor AWD 12-281 in vitro and in vivo. Abstract book of the 18th European Workshop on Drug Metabolism, Sept. 16\u201320, 2002; Valencia, Spain."},{"key":"10.1124\/jpet.103.053942_bib14","doi-asserted-by":"crossref","unstructured":"Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267\u2013279.","DOI":"10.1016\/S0022-3565(24)29537-9"},{"key":"10.1124\/jpet.103.053942_bib15","unstructured":"Hoefgen N, Polymeropoulos E, Egerland U, Poppe H, Marx D, Kronbach T, and Szelenyi S (1999) AWD 12-281, a new PDE 4 inhibitor created by ligand based drug design. Mediators Inflamm 8 (Suppl 1): 104."},{"key":"10.1124\/jpet.103.053942_bib16","doi-asserted-by":"crossref","unstructured":"Howell RE, Jenkins LP, Fielding LE, and Grimes D (1995) Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulm Pharmacol 8: 83\u201389.","DOI":"10.1006\/pulp.1995.1010"},{"key":"10.1124\/jpet.103.053942_bib17","unstructured":"Kuesters S, Marx D, Roellig H, Rudert J, and Szelenyi I (1999) AWD 12-281, a new potent PDE4 inhibitor: in vitro activity and effect on bronchial hyperreactivity (BHR) in BP-2 mice. Am J Respir Crit Care Med 159 (Suppl): A114."},{"key":"10.1124\/jpet.103.053942_bib18","doi-asserted-by":"crossref","unstructured":"Kuss H, H\u00f6efgen N, Egerland U, Heer S, Marx D, Szelenyi I, Schupke H, Gasparic A, Olbrich M, Hempel R, et al. (2002a) AWD 12-281: antiasthmatic\/antiinflammatory phosphodiesterase 4 inhibitor. Drugs Future 27: 111\u2013116.","DOI":"10.1358\/dof.2002.027.02.651710"},{"key":"10.1124\/jpet.103.053942_bib19","unstructured":"Kuss H, H\u00f6efgen N, and Rundfeldt C (2002b) AWD 12-281, a new selective PDE4-inhibitor with a high safety margin: separation of anti-inflammatory and emetic effects in ferrets and domestic pigs. Eur Respir J 20 (Suppl 38): 617s."},{"key":"10.1124\/jpet.103.053942_bib20","unstructured":"Kuss H, H\u00f6efgen N, and Rundfeldt C (2002c) Late phase eosinophilia as an animal model of asthma: effects and time course of the selective PDE4-inhibitor AWD 12-281 in guinea pigs and Brown Norway rats. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 365 (Suppl): R100."},{"key":"10.1124\/jpet.103.053942_bib21","unstructured":"Kuss H, Kasper M, H\u00f6efgen N, and Rundfeldt C (2002d) Inhibition of late phase eosinophilia in allergen challenged Brown Norway rats by AWD 12-281, a new selective PDE4-inhibitor and local tolerability in rat lungs. Am J Respir Crit Care Med 165 (Suppl): A185."},{"key":"10.1124\/jpet.103.053942_bib22","unstructured":"Leichtl S, Seyd J, Bredenbr\u00f6ker D, Rathgeb F, and Wurst W (2002) Efficacy of once daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165 (Suppl): A229."},{"key":"10.1124\/jpet.103.053942_bib23","unstructured":"Marx D, Poppe H, and Szelenyi I (1999) The in vivo activity of AWD 12-281, a potent PDE4 inhibitor for the treatment of allergic asthma. J Allergy Clin Immunol 103 (Suppl): S127."},{"key":"10.1124\/jpet.103.053942_bib24","doi-asserted-by":"crossref","unstructured":"Marx D, Tassabehji M, Heer S, H\u00fcttenbrink K-B, and Szelenyi I (2002) Review: modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm Pharmacol Ther 15: 7\u201315.","DOI":"10.1006\/pupt.2001.0315"},{"key":"10.1124\/jpet.103.053942_bib25","doi-asserted-by":"crossref","unstructured":"Payne AN and De Nucci G (1987) Anaphylaxis in guinea pigs induced by ovalbumin aerosol in vivo and in vitro methods. J Pharmacol Methods 17: 83\u201390.","DOI":"10.1016\/0160-5402(87)90040-4"},{"key":"10.1124\/jpet.103.053942_bib26","unstructured":"Poppe H, Heer S, Sims G, H\u00f6efgen N, and Szelenyi I (2001a) Effects of selective PDE4-inhibitors and \u03b22-agonists on tracheal phenol red secretion in mice and LPS-induced TNF\u03b1 release in human blood. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 363 (Suppl): R111."},{"key":"10.1124\/jpet.103.053942_bib27","unstructured":"Poppe H, H\u00f6efgen N, and Szelenyi I (2000a) Effect of new selective PDE4-inhibitors AWD 12-281 and AWD 12-343 in comparison with SB 207499 and rolipram on LPS-induced neutrophilia in Lewis rat lung, an animal model of COPD. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 361 (Suppl): R118."},{"key":"10.1124\/jpet.103.053942_bib28","unstructured":"Poppe H, Kuesters S, and Szelenyi I (1999) Effect of AWD 12-281, a new selective PDE4-inhibitor, loteprednol and beclomethasone in models of allergic rhinitis and airway inflammation in Brown Norway-rats. Am J Respir Crit Care Med 159 (Suppl): A95."},{"key":"10.1124\/jpet.103.053942_bib29","unstructured":"Poppe H, Marx D, Heer S, Egerland U, H\u00f6efgen N, and Szelenyi I (2001b) Effects of a selective PDE4-inhibitor AWD 12-281 in comparison with SB 207499 and roflumilast on tracheal phenol red secretion in mice and LPS-induced neutrophilia in BAL in Lewis rats and domestic pigs. Am J Respir Crit Care Med 163 (Suppl): A994."},{"key":"10.1124\/jpet.103.053942_bib30","unstructured":"Poppe H, Marx D, and Szelenyi I (2000b) The in vivo activity of AWD 12-281, a potent phosphodiesterase 4 (PDE4) inhibitor for the treatment of allergic asthma and COPD. Allergy 55 (Suppl 63): 968."},{"key":"10.1124\/jpet.103.053942_bib31","unstructured":"Poppe H, Sims G, Helm K-P, and Rundfeldt C (2001c) The selective PDE4-inhibitor AWD 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD: comparison with steroids. Eur Respir J 18 (Suppl 33): 160s."},{"key":"10.1124\/jpet.103.053942_bib32","unstructured":"Poppe H and Szelenyi I (1999) Effect of the new selective PDE4-inhibitor AWD 12-281 and RPR 73401 on LPS-induced neutrophilia in ferret lung and emetogenic effects in conscious ferrets. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 359 (Suppl): R114."},{"key":"10.1124\/jpet.103.053942_bib33","unstructured":"Poppe H, Tschernig T, Hanke M, Pabst R, and Szelenyi I (2000c) Comparison of a new selective PDE4-Inhibitor AWD 12-281 with budesonide on lymphocyte entry and eosinophilia in the bronchoalveolar space of the Brown Norway rat. Am J Respir Crit Care Med 161 (Suppl): A184."},{"key":"10.1124\/jpet.103.053942_bib34","doi-asserted-by":"crossref","unstructured":"Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE, et al. (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113: 1423\u20131431.","DOI":"10.1111\/j.1476-5381.1994.tb17156.x"},{"key":"10.1124\/jpet.103.053942_bib35","doi-asserted-by":"crossref","unstructured":"Schmidt D, Dent G, and Rabe KF (1999) Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 29: 99\u2013109.","DOI":"10.1046\/j.1365-2222.1999.00018.x"},{"key":"10.1124\/jpet.103.053942_bib36","doi-asserted-by":"crossref","unstructured":"Shenkar R and Abraham E (1999) Mechanisms of lung neutrophil activation after haemorrhage or endotoxemia: roles of reactive oxygen intermediates, NF-\u03baB and cyclic AMP response element binding protein. Am Assoc Immunol 163: 954\u2013962.","DOI":"10.4049\/jimmunol.163.2.954"},{"key":"10.1124\/jpet.103.053942_bib37","doi-asserted-by":"crossref","unstructured":"Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, and Minnicozzi M (2001) Comparison of PDE4 inhibitors, rolipram and SB 207499 (Ariflo\u2122), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 14: 157\u2013164.","DOI":"10.1006\/pupt.2001.0291"},{"key":"10.1124\/jpet.103.053942_bib38","doi-asserted-by":"crossref","unstructured":"Tarayre JP, Aliaga M, Barbara M, Tisseyre N, Vieu S, and Tisne-Versailles J (1992) Model of bronchial allergic inflammation in the brown Norway rat. Pharmacological modulation. Int J Immunopharmacol 14: 847\u2013855.","DOI":"10.1016\/0192-0561(92)90083-W"},{"key":"10.1124\/jpet.103.053942_bib39","doi-asserted-by":"crossref","unstructured":"Torphy TJ (1998) Phosphodiesterase isoenzymes, molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 157: 351\u2013370.","DOI":"10.1164\/ajrccm.157.2.9708012"},{"key":"10.1124\/jpet.103.053942_bib40","doi-asserted-by":"crossref","unstructured":"Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, and Compton CH (1999) Ariflo(\u2122) (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 12: 131\u2013135.","DOI":"10.1006\/pupt.1999.0181"},{"key":"10.1124\/jpet.103.053942_bib41","unstructured":"Underwood DC, Bochnowicz S, Osborn RR, Hay DWP, and Torphy TJ (1998) The therapeutic activity of SB 207499 (Ariflo\u2122), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation. Am J Respir Crit Care Med 157 (Suppl): A872."},{"key":"10.1124\/jpet.103.053942_bib42","doi-asserted-by":"crossref","unstructured":"Underwood DC, Matthews JK, Osborn RR, Bochnowicz S, and Torphy TJ (1997) The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig. J Pharmacol Exp Ther 280: 210\u2013219.","DOI":"10.1016\/S0022-3565(24)36414-6"},{"key":"10.1124\/jpet.103.053942_bib43","doi-asserted-by":"crossref","unstructured":"Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, and Torphy TJ (1993) Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 266: 306\u2013313.","DOI":"10.1016\/S0022-3565(25)38342-4"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524309681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524309681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.053942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:34:33Z","timestamp":1739975673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524309681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S0022356524309681"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.053942","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.053942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}